Jefferies confirms its Buy recommendation on the stock with a target of $125 following new data on the AACR cancer vaccine in the head and neck.

' The new data on the HNSCC 2L cancer vaccine are interesting. They show a stronger trial in combo with PD1 compared to what Keytruda alone has shown in previous phase II/III studies' says the analyst.

The data confirm the validity of the INT platform and suggest that it could work in indications other than melanoma," adds Jefferies.

Moderna will rapidly launch pivotal studies, with 3 ongoing studies, and may launch a study in HNSCC.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.